Drugs / Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03665675 | Nov 2020 → Aug 2026 overdue | adenoviridae infectious disease, cytomegalovirus infection, disease related to hematopoietic stem cell transplant, disease related to solid organ transplantation | Sumithira Vasu | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02210078 | Feb 2015 → Aug 2027 expected | cancer, cytomegalovirus infection, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03665675 ↗ |
| Modality | Cell therapy | “White blood cells from donors who have been exposed to cytomegalovirus may be effective in treating patients with a cytomegalovirus infection.” NCT02210078 ↗ |
| Route | Intravenous | “Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes intravenously (IV).” NCT02210078 ↗ |